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factors. Excessive weight and consumption of salt and animalEssential arterial hypertension and stone disease.
proteins may also play an important role.Background. Cross-sectional studies have shown that neph-
rolithiasis is more frequently found in hypertensive patients
than in normotensive subjects, but the pathogenic link between
hypertension and stone disease is still not clear.
A possible association between nephrolithiasis and hy-Methods. Between 1984 and 1991, we studied the baseline
pertension has been suggested by a number of studiesstone risk profile, including supersaturation of lithogenic salts,
conducted in animals and humans. Naturally occurringin 132 patients with stable essential hypertension (diastolic
blood pressure of more than 95 mm Hg) without stone disease kidney stones are rare in animals, but strains of spontane-
and 135 normotensive subjects (diastolic blood pressure less ously hypertensive rats were found to be more prone to
than 85 mm Hg) without stone disease who were matched
developing kidney stones than normotensive ones [1].for age and sex (controls). Subsequently, both controls and
In a trial conducted on a study population of 895 men,hypertensives were followed up for at least five years to check
aged 50 years at the time of examination, 6.8% wereon the eventual formation of kidney stones.
Results. Baseline urine levels in hypertensive males were diagnosed as having kidney stones [2]. When the partici-
different from that of normotensive males with regards to cal- pants were classified according to their blood pressure
cium (263 vs. 199 mg/day), magnesium (100 vs. 85 mg/day), level, the rate of nephrolithiasis increased from 1.1% inuric acid (707 vs. 586 mg/day), and oxalate (34.8 vs. 26.5 mg/
the lower blood pressure class to 13.3% in the upperday). Moreover, the urine of hypertensive males was more
one, which also included treated hypertensive subjects.supersaturated for calcium oxalate (8.9 vs. 6.1) and calcium
phosphate (1.39 vs. 0.74). Baseline urine levels in hypertensive The relationship between blood pressure and rate of
females were different from that of normotensive females with kidney stone disease was found to be statistically signifi-
regards to calcium (212 vs. 154 mg/day), phosphorus (696 vs. cant.614 mg/day), and oxalate (26.2 vs. 21.7 mg/day), and the urine
Furthermore, among patients affected with nephroli-of hypertensive females was more supersaturated for calcium
thiasis, the incidence of hypertension was found to beoxalate (7.1 vs. 4.8). These urinary alterations were only par-
tially dependent on the greater body mass index in hypertensive higher than that of the general population, and a higher
patients. During the follow-up, 19 out of 132 hypertensive mean pressure level was reported in stone formers as
patients and 4 out of 135 normotensive patients had stone opposed to controls [3–5].episodes (14.3 vs. 2.9%, chi-square 11.07, P 5 0.001; odds ratio
The pathogenic link between hypertension and stone5.5, 95% CI, 1.82 to 16.66). Of the 19 stone-former hypertensive
disease is not fully understood. Hypercalciuria is thepatients, 12 formed calcium calculi, 5 formed uric acid calculi,
and 2 formed nondetermined calculi. Of the urinary factors most frequent risk factor for renal stones [6, 7], and some
for lithogenous risk, those with the greatest predictive value studies have reported calcium metabolism disorders in
were supersaturation of calcium oxalate for calcium calculi and
both patients and animals with hypertension, includinguric acid supersaturation for uric acid calculi.
a higher calcium excretion rate [8–11]. Furthermore, epi-Conclusions. A significant percentage of hypertensive sub-
jects has a greater risk of renal stone formation, especially demiological surveys have found a significant correlation
when hypertension is associated with excessive body weight. between arterial pressure and calcium excretion [12–14].
Higher oxaluria and calciuria as well as supersaturation of These observations suggest that the pathogenic link
calcium oxalate and uric acid appear to be the most important
between hypertension and nephrolithiasis might be a
high calcium level. The formation of kidney stones is,
however, a multifactorial event [15], and many otherKey words: calcium oxalate, renal stones, body weight, urine calcium,
urolithiasis, calciuria, blood pressure. urinary stone risk factors have not been tested in hyper-
tensive subjects.Received for publication September 1, 1998
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history of stone disease or silent calculi, versus normo- personal history of nephrolithiasis and with a diastolic
blood pressure level of over 95 mm Hg. We asked thetensive control subjects.
Both hypertensive patients and controls were then 193 subjects fitting this description to collect two 24-
hour urine samples over a Sunday and a workday (forfollowed up for a minimum period of five years in order
monitor any possible stone formation. collection procedure and analysis, see the Urinary stone
risk evaluation section).
We decided to collect urine samples before the screen-
METHODS
ing period in order to avoid the sort of “stone clinic
Patients and controls effect” that can modify diet and urinary physical chemis-
try [20].Between 1984 and 1991, 140 normotensive subjects
(controls, 70 male and 70 female) and 140 patients with These subjects were then screened for secondary
causes of hypertension (3 subjects) and silent urolithiasisstable essential arterial hypertension requiring pharma-
cological treatment (hypertensive subjects, 71 male and (8 subjects) in accordance with a standardized protocol,
which included a renal echography and intravenous pye-69 female) were enrolled in the study, all ranging from
35 to 50 years of age, this being the high-risk age group lography.
During the screening period, we also measured thefor nephrolithiasis [16–18].
Selection of controls. Every year, for a period of eight patient’s body weight, height, and blood pressure.
The importance of body weight, physical exercise, andyears, a random sample population of 1000 persons (half
male and half female), aged between 35 and 50, was diet for arterial hypertension was explained to each pa-
tient.selected from the records kept by the Births, Deaths,
and Marriages Registration Office, and information was Following the guidelines for the treatment of hyper-
tension [21], we identified the patients with stable hyper-sent to them regarding the study. Healthy subjects wish-
ing to volunteer were invited to contact one of the physi- tension, and only the subjects who continued to present
with a diastolic pressure equal to or greater than 95 mmcians involved in the research project.
A total of 492 persons volunteered, but only 204 ful- Hg throughout the entire screening period (two to three
months), despite the dietary measures and physical pre-filled inclusion criteria requirements, which included dia-
stolic pressure that was equal or inferior to 85 mm Hg, cautions taken, were included in the study.
In this way, over a period of eight years, we were ableno use of drugs, no medical history of renal lithiasis or
suspected colic, no medical history of bone disease or to enroll 140 patients who were definitely affected by
stable essential arterial hypertension requiring pharma-other relevant alterations, no silent kidney stones (veri-
fied by renal echography and abdominal x-ray), normal cological treatment but not suffering from stone disease.
As per the controls, the arterial pressure reported is therenal function (glomerular filtration rate by creatinine
clearance of more than 80 ml/min), and normal serum mean value calculated on a minimum of six readings.
Both controls and hypertensive subjects were classifiedglucose, uric acid, calcium, and phosphate levels.
In order to be absolutely certain that the subjects en- as having a family history of stone disease if they had
at least one grandparent, one parent, or one sibling withrolled were normotensive, we followed them for at least
two months, measuring their arterial pressure on at least a history of kidney stones (family history self-reported).
six occasions using a mercury sphygmomanometer in ac-
Urinary stone risk evaluationcordance with the recommendations of the Subcommittee
of the AHA Postgraduate Education Committee [19]. As For each control and hypertensive subject, we ar-
ranged two days of urine collection over a Sunday anda result, a further 64 subjects were excluded from final
enrollment because they presented with a mean diastolic a workday, in normal lifestyle and free diet conditions.
The subjects were specifically asked not to change theirpressure (calculated on the six measurements taken)
greater than 85 mm Hg. The 140 subjects finally judged eating and drinking habits, and each received written
instructions relative to urine collection methods.to be absolutely normotensive were definitively enrolled
for evaluation of the urinary lithogenous risk and subse- None of the subjects were under pharmacological
treatment at the time of the urine collection. As pub-quent follow-up (discussed later in this article). They were
asked not to change their dietary habits in any way. lished elsewhere, the evaluation of urinary stone risk
in our laboratory included 24-hour urine volume, pHSelection of hypertensive subjects. Each year, an aver-
age of 50 hypertensive subjects are referred by their (pH meter), creatinine (Jaffe´ method), sodium, potas-
sium, calcium and magnesium (atomic absorption spec-general physicians to our university hospital for an initial
diagnostic assessment and to exempt them from payment trophotometry), chloride (electrochemical titration), uric
acid (uricase method), sulfate, phosphorus and oxalatefor antihypertensive drugs.
From this “pool” of approximately 400 patients, we (ion-chromatographic technique), citrate (citrate lyase
method), urea (urease method), ammonium (colorimet-selected those aged between 35 and 50 with a negative
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ric method by Berthelot), cystine (colorimetric method relative risk of stone formation associated with blood
hypertension.by phosphotungstic acid), and glycosaminoglycans (GAG;
hexuronic acid determination) [22]. Stepwise discriminant analysis was performed among
hypertensive stone formers and hypertensive nonstoneSupersaturation calculations for calcium oxalate, cal-
cium phosphate, uric acid, and struvite were obtained formers in order to identify independent abnormalities
and stone predictors among the baseline urinary stoneusing the computer program Equil [23]. A result of less
than one indicates undersaturation, whereas a result of risk factors.
All statistical analyses were performed on a personalmore than one indicates supersaturation.
For all of the urinary stone risk factors reported, the computer using the SPSS software package.
mean value of the two measurements was calculated.
RESULTSFollow-up
Because nephrolithiasis can be affected by occupationBoth controls and hypertensive subjects were fully
[15, 24, 25], an analysis was carried out “a posteriori”informed of the nature of the study, and all of them
on the types of occupation, and no differences wereconsented to a follow-up of at least five years, involving
observed between the normotensive and hypertensivean annual clinical examination and renal echography to
group.check for the formation of stones.
Five controls (four men and one woman) and eightOnce the baseline study had been concluded, the hy-
hypertensive subjects (five men and three women) failedpertensive subjects began pharmacological treatment
to respect the follow-up time and were therefore consid-with one or more antihypertensive drugs in order to keep
ered as dropouts and were not included in the calcula-pressure values under control. At the outset these drugs
tions.were Ca antagonists, angiotensin-converting enzyme in-
The characteristics of the subjects who successfullyhibitors, or thiazides. During the follow-up, the patients’
finished the study are shown in Table 1.family doctors were responsible for controlling pressure
The glomerular filtration rate was higher in hyperten-and prescribing pharmacological treatment, and we were
sive men, but when it was corrected for 1.73 m2 bodynot informed as to changes made in dosages or drugs.
surface area, the difference ceased to exist.Both controls and hypertensive subjects were only re-
Both male and female hypertensive subjects differedquired to report to us once a year for the echography
from controls regarding anthropometric data in that thespecified by the protocol or following the symptoms of
body weight, BMI, and body surface area were higher.renal stones.
The natural expulsion of a stone, the presence of a Serum and urine baseline study
silent stone revealed by echography, a typical renal colic
No differences in baseline serum levels of glucose,with the expulsion of gravel and hematuria were all con-
urea, calcium, phosphate, magnesium, sodium, and po-sidered to be stone episodes. When silent stones were
tassium were found between hypertensive patients andrevealed by echography, an abdominal x-ray was also
controls (data not reported).carried out, and if judged to be the best course of action,
In hypertensive men, the mean values of serum choles-appropriate measures were taken to remove the calculi.
terol (217 6 5 vs. 201 6 5 mg/dl, P 5 0.021), triglyceridesThe stones passed, or their fragments were analyzed
(158 6 9 vs. 124 6 5 mg/dl, P 5 0.003), and uric acidby wet chemical methods or by an x-ray diffraction tech-
(5.7 6 0.1 vs. 5.2 6 0.08 mg/dl, P 5 0.012) were highernique when material was very scarce.
than in control men.
In hypertensive women, only the mean values of serum
Statistics cholesterol were higher than in control women (210 6
5 vs. 191 6 3 mg/dl, P 5 0.005).All data are expressed as a mean 6 sem.
Levene’s test for equality of variances and Student’s The urinary baseline stone risk profile in essential hy-
pertensive patients and controls is shown in Table 2.unpaired t-test for equality of means were used to com-
pare mean values in hypertensive patients and controls, The urine of hypertensive men differed from that of
control men in that they had a higher excretion of cal-which were subdivided according to sex.
Associations among variables were assessed by Pear- cium, magnesium, uric acid, and oxalate. Furthermore,
the urine of hypertensive men was more supersaturatedson’s correlation coefficients.
Analyses of covariance were used to adjust urinary for calcium oxalate and calcium phosphate.
The urine of hypertensive women differed from thatstone risk factors for body mass index (BMI).
Differences in frequency were tested by chi-square of control women with regards to a higher excretion
of calcium, phosphorus, and oxalate. It was also moreanalysis. In addition, the odds ratio and 95% confidence
interval were taken as an approximate estimate of the supersaturated for calcium oxalate.
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Table 1. Characteristics of hypertensive patients and controls
Men Women
Controls Hypertensives Controls Hypertensives
(N 5 66) (N 5 66) P (N 5 69) (N 5 66) P
Age years 41.660.6 42.9 60.6 0.11 42.760.7 42.6 60.6 0.95
Weight kg 74.460.9 82.7 61.7 0.0001 58.760.8 64.8 61.6 0.001
Height cm 17360.8 174 60.8 0.70 16260.7 162 60.6 0.57
BMI kg/m2 24.660.3 27.2 60.4 0.0001 22.260.3 24.7 60.6 0.0001
BSA m2 1.8860.01 1.97 60.02 0.001 1.6260.01 1.68 60.02 0.01
SBP mm Hg 12961 151 61.4 0.0001 12261.5 147 61.4 0.0001
DBP mm Hg 7760.6 10260.8 0.0001 7560.7 10060.6 0.0001
MBP mm Hg 9560.7 11860.9 0.0001 9160.9 11660.8 0.0001
CCr ml/min 11562 126 63 0.01 10162 103 62 0.60
Corr. CCr ml/min 10662 110 62 0.20 10862 106 62 0.52
Family history of stone disease 13.6% 19.7% 0.35 15.9% 16.7% 0.91
Data are mean 6 sem; P value is by Student’s t-test for unpaired data.
Abbreviations are: BMI, body mass index; BSA, body surface area; SBP, systolic blood pressure, MBP, mean blood pressure; CCr, creatinine clearance; Corr. CCr,
corrected creatinine clearance (CCr 3 1.73/BSA).
Table 2. Baseline urinary stone risk profile in hypertensive patients and controls
Men Women
Controls Hypertensives Controls Hypertensives
(N 5 66) (N 5 66) P (N 5 69) (N 5 66) P
Volume ml/day 1425664 1501 669 0.42 1263 657 1357 665 0.20
Sodium mmol/day 17867 183 68 0.60 145 65 147 66 0.81
Potassium mmol/day 5662 60 63 0.21 51 62 54 62 0.37
Chloride mmol/day 17867 194 69 0.15 146 66 150 66 0.63
Calcium mg/day 199610 263 614 0.0001 154 68 212 611 0.0001
Phosphorus mg/day 777629 847 632 0.09 614 626 696 625 0.026
Magnesium mg/day 8564 10064 0.01 72 64 76 63 0.44
Urea g/day 24.660.8 26.8 60.9 0.09 19.4 61.1 18.7 60.8 0.64
Sulfate mmol/day 2160.5 22 60.8 0.15 17 60.4 18 60.5 0.35
Ammonium mmol/day 3961 38 61 0.64 29 61.1 28 61.1 0.43
Uric acid mg/day 586621 707 630 0.001 501 622 498 617 0.90
Oxalate mg/day 26.561.2 34.8 61.3 0.0001 21.7 60.8 26.2 60.9 0.001
Cystine mg/day 8165 80 65 0.95 73 64 72 65 0.79
Citrate mg/day 566628 530 629 0.37 689 634 650 630 0.39
GAG mg/day (31) 7.160.3 (43) 7.7 60.5 0.34 (37) 5.7 60.2 (28) 5.6 60.3 0.74
pH, 24 hr 5.8560.05 5.91 60.06 0.45 6.07 60.06 5.95 60.06 0.19
CaOx SS 6.160.5 8.9 60.5 0.0001 4.8 60.3 7.1 60.4 0.0001
CaP SS 0.7460.05 1.39 60.13 0.0001 0.87 60.09 1.00 60.8 0.33
Uric acid SS 2.9 60.2 3.2 60.3 0.45 2.1 60.2 2.5 60.3 0.28
Struvite SS 0.0660.02 0.13 60.05 0.19 0.12 60.03 0.08 60.02 0.33
Data are mean 6 sem; P value is by Student’s t-test for unpaired data.
Abbreviations are GAG (glycosoaminoglycans) were detected in some of the subjects (the number is in brackets); CaOx SS, CaP SS, Uric acid SS, and Struvite
SS, supersaturations by Equil 2 for calcium oxalate, calcium phosphate, uric acid and struvite.
No differences were detected for the other urinary Table 3 shows that in overweight hypertensive males,
the urinary stone risk factors (calcium, oxalate, and uricstone risk factors evaluated.
Because hypertensive subjects tend to have a greater acid) were higher than in hypertensive males with a nor-
mal BMI, whereas less significant differences were ob-body size and because the BMI was positively correlated
to many of the urinary parameters giving different values served in the stone inhibitors (magnesium, citrate, and
GAG).compared with normotensive subjects (Pearson’s corre-
lations BMI calcium r 5 0.34, P 5 0.0001; BMI phospho- These data, referred to as nutritional markers, sug-
gested that a higher intake of salt and animal proteinsrus r 5 0.43, P 5 0.0001; BMI uric acid r 5 0.44, P 5
0.0001; BMI oxalate r 5 0.36, P 5 0.0001; BMI magne- existed in overweight hypertensive males; that is, these
patients had higher levels of sodium, urea, sulfate, phos-sium r 5 0.30, P 5 0.0001), we divided the hypertensive
patients into two groups: those with a normal BMI and phorus, and creatinine.
In overweight hypertensive females, these differencesthose with a high BMI (, 26 . male and , 24 . female).
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Table 3. Urinary parameters in hypertensive men and women, divided by normal or high body mass index (BMI)
Hypertensive men (N 5 66) Hypertensive women (N 5 66)
BMI,26 BMI.26 BMI ,24 BMI.24
(N 5 23) (N 5 43) P (N 5 32) (N 5 34) P
Urinary parameters
Stone risk factors
Calcium mg/day 208616 293617 0.003 180 615 243614 0.003
Oxalate mg/day 2961.4 37.961.7 0.0001 26.2 61.5 26.161.2 0.93
Uric acid mg/day 562635 784636 0.0001 464 621 530626 0.058
Stone inhibitors
Magnesium mg/day 8865 10666 0.052 71 65 8065 0.22
Citrate mg/day 505640 543639 0.53 574 644 723636 0.011
GAG mg/day (17) 6.5 60.6 (26) 8.5 60.8 0.073 (13) 5.5 60.6 (15) 5.7 60.4 0.79
Nutritional markers
Sodium mmol/day 160612 196611 0.038 135 67 15869 0.066
Potassium mmol/day 5665 6263 0.31 50 63 5863 0.09
Urea g/day 22.261.3 29.361.1 0.0001 17.2 61.1 20.161.3 0.10
Sulfate mmol/day 19.761.2 23.960.9 0.012 16.7 60.8 18.760.6 0.065
Phosphorus mg/day 724635 913642 0.001 605 632 782632 0.0001
Creatinine mg/day 1557646 1947676 0.0001 1171 653 1246640 0.26
Data are mean 6 sem; P value is by Student’s t-test for unpaired data.
GAG (glycosoaminoglycans) were detected in some of the subjects (the number is in brackets).
Table 4. Mean values adjusted for body mass index (BMI) of the tensive males, oxalate and supersaturations of calcium
urine parameters found different in hypertensive patients
oxalate and calcium phosphate remained higher, whereas
Controls Hypertensives P in hypertensive females, calcium, oxalate, and supersatu-
Men ration of calcium oxalate remained higher.
Mean calcium adjusted
mg/day 215 247 0.069 Follow-up study
Mean magnesium adjusted
mg/day 89 95 0.31 The mean length of the follow-up was 7.78 6 0.17
Mean uric acid adjusted years in the control group (range 5.25 to 12.41 years)
mg/day 625 668 0.23
and 7.59 6 0.19 years in the hypertensive group (rangeMean oxalate adjusted
mg/day 27.9 33.5 0.004 5.08 to 12 years).
Mean CaOx SS adjusted 6.5 8.6 0.009 During this period, 4 out of 135 normotensive subjects
Mean CaP SS adjusted 0.84 1.29 0.005
and 19 out of 132 hypertensive patients had a renal stoneWomen
Mean calcium adjusted episode: 2.9 and 14.3%, respectively (chi-square value
mg/day 156 209 0.0001 11.07, P 5 0.001).Mean phosphorus adjusted
The risk of stone formation was significantly highermg/day 630 682 0.14
Mean oxalate adjusted in hypertensive patients than in normotensive controls
mg/day 21.9 26.0 0.003 (odds ratio 5.5, 95% CI, 1.82 to 16.66).Mean CaOx SS adjusted 4.9 7.0 0.001
Table 5 reports some clinical information on subjects
who had stone episodes during the follow-up.
Among the controls, we were able to identify stone
composition in three out of four subjects (two calciumwere less evident, but it was possible to demonstrate
and one uric acid stone). Among the hypertensive pa-distinctly higher urinary calcium and citrate values. Con-
tients, when it was not possible to analyze the stone,cerning the nutritional markers, data suggesting greater
x-ray radiopaque material was defined as a calcium stone,salt and animal protein consumption in overweight hy-
and x-ray radiolucent material was defined as a uric acidpertensive females showed a less marked trend as com-
stone. In this way, we were able to establish a calciumpared with males, although the trend was nonetheless
stone composition in 12 out of 19 patients (patients num-detectable.
bers 1 to 12) and a uric acid stone composition in 5 outPotassium values did not show any significant differ-
of 19 (patients numbers 13 to 17); in two patients, it wasences in either males or females with regards to over-
not possible to define stone composition (patients 18 andweight subjects and subjects with a normal BMI.
19) because the stone was not seen (the likely cause ofFollowing the adjustment for the BMI (Table 4), the
the renal colic and hematuria was gravel).differences in calcium excretion, magnesium and uric
In seven other cases, the formation of stones in hyperten-acid decreased in males, whereas in females, only the
difference in phosphorus excretion decreased. In hyper- sive subjects occurred asymptomatically and was only ob-
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Table 5. Clinical information about subjects who had a stone episode during the follow-up period
Sex BMI Composition Time Presentation Removal
Controls
1 M 26.2 CaOx 100% (fragments) 5.58 Silent ESWL
2 M 25.3 CaOx 100% 6.41 Renal colic Expulsion
3 M 23.8 Unknown 3.66 Hematuria Gravel?
4 F 25.3 Uric acid 100% 7.25 Renal colic Expulsion
Hypertensives
1 M 26.9 CaOx 95% 1 CaP 5% 2.33 Renal colic Expulsion
2 M 21.9 CaOx 100% 3.66 Renal colic Expulsion
3 M 32.1 CaOx 65% 1 CaP 35% 7.75 Renal colic Basket
4 M 22.4 CaOx 90% 1 CaP 10% 6.75 Renal colic Expulsion
5 M 27 X-ray opaque (calcium) 4.41 Silent No removal
6 M 25.3 CaOx 100% (fragments) 3.58 Silent ESWL
7 M 29.2 X-ray opaque (calcium) 6.16 Silent No removal
8 M 35.8 CaOx 90% 1 CaP 10% 4.66 Renal colic Expulsion
9 F 27.5 CaOx 100% (fragments) 3.08 Silent ESWL
10 F 24.2 X-ray opaque (calcium) 4.66 Silent No removal
11 F 35.4 CaOx 95% 1 CaP 5% 6.25 Renal colic Basket
12 F 25.6 CaOx 100% (fragments) 5.58 Silent ESWL
13 M 29.4 Uric acid 100% 5.16 Hematuria Expulsion
14 M 27.5 Uric acid 80% 1 CaOx 20% 6.16 Renal colic Expulsion
15 M 26.4 X-ray radiolucent (uric acid) 6.33 Silent No removal
16 M 26.7 Uric acid 100% 10.75 Renal colic Basket
17 F 23.5 Uric acid 100% 5.5 Renal colic Expulsion
18 M 31.5 Unknown 8.33 Renal colic Gravel?
19 F 22.9 Unknown 11.33 Hematuria Gravel?
Definitions are: BMI, body mass index; composition, type of stones formed; time, years passed between baseline study and stone discovery; presentation, way of
stone discovery; removal, kind of stone removal.
Table 6. Discriminant analysis of the urinary characteristics thatserved during the periodical echographic and radiographic
differentiate between hypertensive stone formers and
examinations carried out during the follow-up period; hypertensive calculi free
three of these seven cases were subsequently treated with
Predicted groupextracorporeal shock wave lithotripsy (ESWL) with a final membership
confirmation that they were actually renal stones.
CaOx SS in hypertensive calcium stone formers
Table 5 also shows the BMI of stone formers, recorded Actual group No. of cases Stone formers Calculi free
Calcium stone formers 12 8 (66.7%) 4 (33.3%)at the beginning of the follow-up period. Among the 23
Hypertensive calculi free 113 30 (26.5%) 83 (73.5%)subjects who produced stones, 16 were overweight. A
Uric Acid SS in hypertensive uric acid stone formers
statistical comparison between stone formers and non- Actual group No. of cases Stone formers Calculi free
Calcium stone formers 5 3 (60%) 2 (40%)stone formers gave a statistically significant result regard-
Hypertensive calculi free 113 23 (20.4%) 90 (79.6%)ing the BMI (chi-square value, 6.9, P 5 0.009), suggesting
a higher lithogenous risk in overweight subjects.
The urinary baseline characteristics of the 12 hyper-
tensive calcium stone formers and the 5 hypertensive uric
in a category at risk for the formation of renal calculiacid stone formers were studied by stepwise discriminant
because they present certain urinary abnormalities com-analysis and were compared with the urinary baseline
monly encountered in stone formers.characteristics of the hypertensive subjects who re-
In fact, baseline urinary values in hypertensive malesmained calculi free during the follow-up. The discrimi-
were different than those of normotensive males inas-nant function (Table 6) identified calcium oxalate super-
much as they had greater amounts of calcium, oxalate,saturation in calcium stone formers and uric acid
and uric acid, and although they contained greater levelssupersaturation in uric acid stone formers as the main
of magnesium, they were more supersaturated with re-urinary predictors. The percentage of “grouped” cases
gards to calcium oxalate and calcium phosphate. Also,correctly classified was 72.8% by calcium oxalate super-
in hypertensive females, the urine values were character-saturation and 78.8% by uric acid supersaturation.
ized by higher excretion of calcium and oxalate resulting
in a higher supersaturation of calcium oxalate.
DISCUSSION Over the last 50 years, the incidence of arterial hyper-
This article suggests that patients with stable essential tension and nephrolithiasis has markedly increased, be-
coming an important social and economic problem.arterial hypertension, especially when overweight, are
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Some epidemiological studies have confirmed that there [59–62], which could explain the discovery of hypercalci-
uria in a significant subgroup of these subjects.is a positive association between the two diseases [2,
Other epidemiological studies, on the other hand,26–29], and recently, it was reported that a history of
seem to suggest that hypertensive subjects and stonehypertension was the only clinical parameter correlated
formers have similar dietary habits, characterized aboveto papillary calcification in cadaveric kidneys [30]. The
all by a low calcium intake [63–65], which, as is well-reasons behind this association are not yet fully under-
known, can lead to increased oxaluria as a result ofstood. In chronological terms, it appears that nephrolithi-
augmented intestinal absorption of oxalate [66, 67]. Thisasis manifests itself before arterial hypertension [29], but
hypothesis is born out by the fact that a calcium-richthis does not necessarily imply that there is a causal
diet seems to favor the reduction of arterial pressurerelationship between the two. A possible hypothesis
levels and the risk of renal stone formation [68, 69].might be that a portion of hypertensive subjects with
Still on the subject of nutrition, both hypertensivecalculosis tends to have a common genetic, metabolic,
subjects and stone formers generally have a higher bodyand nutritional substrate that expresses itself in early life
weight when compared with control groups, leading toin the form of nephrolithiasis and in later life in the form
the conclusion that body weight must play a role in bothof arterial hypertension.
diseases. Recent wide-reaching epidemiological studiesWe compared two groups of patients, matched for
confirmed that an increase in body weight, even slight,age and sex, with no history of kidney stones and with
is strongly correlated to the risk of hypertension andmarkedly different diastolic pressure levels.
stone disease [70, 71].We found that the basic lithogenous risk is, in fact,
The scope of our study did not allow us to carry outhigher for a significant percentage of the hypertensive
an in-depth investigation of diet, but certain elementssubjects and that part of them tend to form stones, even
suggest a different metabolic–nutritional picture in thewhen the hypertension is pharmacologically treated.
hypertensive patients in our study versus the normoten-Hypercalciuria is undoubtedly an important risk factor
sive subjects.for the formation of calcium oxalate calculi, and research
Both males and females had higher cholesterol serumhas revealed the existence of calcium metabolism alter-
levels. The males also had higher serum levels for triglyc-ations, including increased renal excretion both in hyper-
erides and uric acid, whereas both males and femalestensive animals [1, 31–33] and humans [10, 11, 34–40].
had a higher BMI.We confirm this finding and are in agreement with the
These data are indicative of a diet rich in calories, fats,authors who advance the hypothesis that increased renal
and carbohydrates, which has been associated with acalcium excretion could be a pathogenic link between
higher metabolic production of uric acid and oxalate
hypertension and nephrolithiasis [41–45].
[72–74].
However, it also emerged from our study that urinary The BMI is a particularly significant element because
oxalate levels were higher in hypertensive subjects of oxalate excretion has recently been found to correlate
both sexes, and that hypertensive men tended to have directly with body size in normal subjects as well [75].
higher urinary uric acid levels. In our hypertensive patients, the BMI correlated well
It is a well-known fact that a small increase in urinary to excretion of the most important stone risk factors:
oxalate increases the lithogenous risk for calcium oxalate calcium, oxalate, and uric acid, and when hypertensive
[46], whereas hyperuricosuria can favor the formation subjects were divided into groups with a normal or high
of both uric acid and calcium stones [6, 47–49]. BMI, significant differences were observed in the urinary
On the whole, these findings suggest that hypertensive excretion of lithogenous factors as well as of certain
subjects usually harbor a higher lithogenous risk than known nutritional markers.
normotensive ones, and this might explain the frequent In particular, it was observed that the urine of over-
association between the two diseases. weight hypertensive subjects showed a higher stone risk
The scope of our work does not allow us to make a associated with higher levels of sodium, urea, sulfate,
pathogenic interpretation of these findings, but we can, phosphorus, and creatinine, which in the presence of
nonetheless, advance some hypotheses. normal renal function are acknowledged to be valid
Cell alterations concerning abnormal transport of so- markers of the dietary intake of salt and animal proteins
dium, calcium, and oxalate [50–58] have been described [76–79].
for both stone forming and hypertensive subjects. These These differences were more evident in hypertensive
alterations could form a kind of genetic substrate fa- males but were also observed in the females. Of course,
voring the onset of both diseases [44]. Some hormonal the detection of a higher creatinine excretion level in
similarities are also to be found between hypertensive hypertensive males with a high BMI, a phenomenon not
and stone-forming subjects, such as, for example, in- encountered in the females, could also be due to the
greater muscle mass peculiar to this group of subjects.creased levels of 1,25(OH)2D and parathyroid hormone
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It is, however, well-known that a high sodium intake hypertensive males, and of up to 32.8% in hypertensive
males treated with antihypertensive drugs [27].increases the stone risk as it may induce hypercalciuria
Regarding the chemical composition of the stones[80–87] and that an excess of animal proteins can cause
formed by the hypertensive subjects, we were able to es-marked increases in the excretion of calcium, oxalate,
tablish that 12 were calcium stones and 5 uric acid stones.and uric acid [88, 89].
The stepwise discriminant analysis pointed out thatIt should be underlined that in our personal experi-
the most important predictive factor in the 12 subjectsence, the role of NaCl intake seems to be considerable
who had formed calcium stones was calcium oxalate su-in many hypertensives in that it maintains a high blood
persaturation, whereas in the 5 subjects who had formedpressure and induces a high calcium excretion.
uric acid stones, the most discriminating factor was uricIn all of our subjects, there was no relevant difference
acid supersaturation.in NaCl excretion between hypertensives and controls;
This result is fully consistent with a recent article thathowever, a hypersensibility to salt is proven in many
reported an excellent correspondence between the su-hypertensive subjects, and it is associated with genetic
persaturation levels of lithogenous salts and the type offactors, which were recently analyzed and supposed to
stones produced in a large population of stone formersbe a possible pathogenic mechanism of salt-dependent
[93].hypertension [90].
Concerning the type of antihypertensive treatment fol-In these conditions, the volume expansion caused by
lowed by the hypertensive patients, it was not possibleNaCl retention may be produced by an excretion defect,
to reach any conclusion.and it may play an important role in calcium excretion
The pharmacological treatment was administered byincrease on the same NaCl supply.
the family doctor who would increase or modify theIn addition, an extracellular volume expansion and a
dosage with a view to maintaining the best possible pres-salt-dependent hypertension has been often noticed in
sure levels. In general, the drugs used were thiazides,overweight subjects [91, 92].
calcium antagonists, angiotensin-converting enzyme in-When, however, the urinary data relative to lithogen-
hibitors, b-blockers, and clonidine. Loop diuretics wereous risk were corrected for the BMI, a persistent differ-
never administered over long periods of time. In a smallence was observed in the levels of oxalate and in the
number of cases, the treatment was stopped within thissupersaturation values for calcium oxalate in hyperten-
time period, as it was possible to keep the blood pressuresive males as well as females.
under control with nonpharmacological methods. In anyThis finding suggests that hypertension per se may be
event, we do not have the necessary data to be ableaccompanied by higher levels of urinary oxalate with
to say whether the type of pharmacological treatment
mechanisms that are still unknown.
administered or pressure control methods used actually
The role of body size also has been confirmed by the influenced the formation of renal stones.
follow-up data. The only observation that we were able to make was
In fact, of the 23 subjects who developed nephrolithia- that none of the subjects who formed stones had used
sis (19 of whom were hypertensive and 4 of whom normo- thiazides on a regular basis.
tensive), 16 were overweight, and the statistical analysis In summary, this study has demonstrated that a sig-
was in favor of a significant association with BMI. nificant percentage of the subjects who suffer from stable
The aim of our study was not to assess the prevalence essential arterial hypertension present a urinary physio-
of nephrolithiasis in hypertensive subjects, a topic that chemical profile with a greater stone risk than normoten-
would require an extensive epidemiological assessment sive subjects matched for sex and age. This greater risk
that did not fall within the scope of our investigation. appears to be, at least partially, of a metabolic–nutri-
The percentage of stone formers (14.3%) that was tional nature, but this aspect requires to be further inves-
recorded in our group of hypertensive subjects may seem tigated.
high if we fail to take into account the fact that we were The most important predictive factors for chemical
investigating a selected group in an age range that is composition appear to be the supersaturation of litho-
particularly at risk for the formation of stones [16–18]. genous salts, calcium oxalate, and uric acid.
Furthermore, it must also be stressed that in 7 out of 19 From a practical point of view, this study suggests
cases, the early formation of silent calculi was detected, that hypertensive subjects, especially when overweight,
and this would not have been identified in an analysis would do well to adopt the preventive dietary measures
based on only the clinical expression of lithiasic disease. that are generally recommended to subjects who have
On the other hand, even though not directly comparable had previous stone episodes: a reduction in the intake
with our study, reports concerning the history of nephro- of calories and animal protein and salt while maintaining
lithiasis in hypertensive subjects quote percentages of up a normal intake of calcium and increasing water con-
sumption. The possible role played by antihypertensiveto 13.3% in 50-year-old males [2], 20.3% in nontreated
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